Major Depressive Disorder (DSM-5) – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of major depressive disorder (MDD) (DSM-5) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of MDD (DSM-5) for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

Clarivate Epidemiology’s MDD (DSM-5) forecast will answer the following questions:

  • Of all people with MDD (DSM-5), how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with MDD (DSM-5), how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MDD (DSM-5) over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology forecasts the following MDD (DSM-5) patient population:

  • Total prevalent cases.

Note: Coverage may vary by country.

Table of contents

  • Major Depressive Disorder (DSM-5) - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
      • Total 12-Month Prevalence of Major Depressive Disorder (DSM-5) per 1,000 People Aged 15+ in 2021 and 2041ttttttttt
      • Relative Sizes of the Factors Contributing to the Trend in Total 12-Month Prevalent Cases (DSM-5) of Major Depressive Disorder over the Next 20 Yearsttttttttt
    • Epidemiology Data
    • Methods
      • Total 12-Month Prevalent Cases
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Major Depressive Disorder (DSM-5)
        • Studies Excluded from the Analysis of Major Depressive Disorder (DSM-5)
      • Risk/Protective Factors
        • Risk/Protective Factors for Major Depressive Disorder (DSM-5)
      • Bibliography
      • Abbreviations
      • Glossary